Hematopoiesis News Volume 7.11 | Mar 22 2016

Mitotic History Reveals Distinct Stem Cell Populations and Their Contributions to Hematopoiesis
Using a conditional histone 2B-mCherry-labeling mouse model, scientists characterized hematopoietic stem cell and progenitor proliferation dynamics in steady state and following several types of induced stress. [Cell Rep] Full Article | Graphical Abstract

Genome-Wide RNAi Screen Identifies Cohesin Genes as Modifiers of Renewal and Differentiation in Human HSCs
To gain insights into the regulatory mechanisms of hematopoietic stem cells (HSCs), researchers employed a genome-wide RNAi screen in human cord-blood derived cells and identified candidate genes whose knockdown maintained the HSC phenotype during culture. [Cell Rep] Full Article | Graphical Abstract | Press Release

Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis
Among various types of hematopoietic cells in bone marrow, interleukin-27 predominantly and continuously promoted the expansion of only Lineage⁻Sca-1⁺c-Kit⁺ cells, especially long-term repopulating hematopoietic stem cells and myeloid-restricted progenitor cells with long-term repopulating activity, and the differentiation into myeloid progenitors in synergy with stem cell factor. [PLoS Pathog] Full Article

CDKIs p18^INK4c and p57^Kip2 Are Involved in Quiescence of CML Leukemic Stem Cells after Treatment with TKI
The authors analyzed cell cycle status, the levels of several cyclin dependent kinase inhibitors (CDKIs) and the subcellular localization of such molecules in different chronic myeloid leukemia (CML) cell lines, as well as primary CD34⁺CD38⁻lin⁻ leukemic stem cells and hematopoietic stem cells. [Cell Cycle] Abstract

Meis1 Is Required for Adult Mouse Erythropoiesis, Megakaryopoiesis and Hematopoietic Stem Cell Expansion
Findings obtained from two inducible Meis1 knockout models confirm and extend previous reports of the essential role of Meis1 in adult hematopoietic stem cell maintenance and expansion and provide new evidence that highlights key roles of Meis1 in both megakaryopoiesis and erythropoiesis. [PLoS One] Full Article

CLINICAL RESEARCH

Late Effects in Patients with Fanconi Anemia following Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Donors
Researchers performed a retrospective analysis of 22 patients with Fanconi anemia and aplastic anemia, myelodysplastic syndrome or acute myelogenous leukemia who underwent a hematopoietic stem cell transplantation (HSCT) at Memorial Sloan Kettering Cancer Center and survived at least one year post HSCT. [Bone Marrow Transplant] Abstract

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia
The authors report the outcome of stem cell transplantation in 22 patients with T315I⁺ chronic myeloid leukemia patients, the majority of which from haploidentical family donors. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Celator Announces Phase III Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival
Celator Pharmaceuticals, Inc. announced positive results from the Phase III trial of VYXEOS™ Liposome for Injection in patients with high-risk acute myeloid leukemia compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. [Press release from Celator Pharmaceuticals, Inc. discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.

Collaboration to Develop Cancer Therapeutics
Harvard University has entered into an exclusive license and research collaboration agreement with Merck to further the development of small-molecule therapeutics for leukemia and other cancers. The novel compounds, developed in the laboratory of Harvard scientist Matthew Shair, offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription. [Harvard University] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Postdoctoral Fellow – Molecular and Cellular Basis of Hematopoiesis (University of Cincinnati)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow Positions – Leukemogenesis (The University of Alabama)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University Health Center)

Postdoctoral Fellow – Cancer Biology (National University of Singapore)

PhD Position – Leukemogenesis and Treatment Resistance (Institute for Tumor Biology and Experimental Therapy)

Translational Research Scientist – Hematology/Oncology (University of Chicago)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford Burnham Prebys Medical Discovery Institute)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.